WallStSmart

Novartis AG ADR (NVS)vsOraSure Technologies Inc (OSUR)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Novartis AG ADR generates 50333% more annual revenue ($56.69B vs $112.41M). NVS leads profitability with a 22.5% profit margin vs -43.7%. NVS appears more attractively valued with a PEG of 3.22. NVS earns a higher WallStSmart Score of 51/100 (C-).

NVS

Buy

51

out of 100

Grade: C-

Growth: 4.0Profit: 9.0Value: 3.3Quality: 4.5
Piotroski: 4/9Altman Z: 1.96

OSUR

Hold

40

out of 100

Grade: F

Growth: 4.0Profit: 2.0Value: 4.0Quality: 8.5
Piotroski: 3/9Altman Z: 3.08
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

NVSSignificantly Overvalued (-47.0%)

Margin of Safety

-47.0%

Fair Value

$93.29

Current Price

$137.16

$43.87 premium

UndervaluedFair: $93.29Overvalued

Intrinsic value data unavailable for OSUR.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

NVS5 strengths · Avg: 9.4/10
Market CapQuality
$260.70B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
30.7%10/10

Every $100 of equity generates 31 in profit

Operating MarginProfitability
34.6%10/10

Strong operational efficiency at 34.6%

Profit MarginProfitability
22.5%9/10

Keeps 23 of every $100 in revenue as profit

Free Cash FlowQuality
$5.57B8/10

Generating 5.6B in free cash flow

OSUR4 strengths · Avg: 9.5/10
Price/BookValuation
0.7x10/10

Reasonable price relative to book value

Debt/EquityHealth
0.0410/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
3.0810/10

Safe zone — low bankruptcy risk

EPS GrowthGrowth
29.6%8/10

Earnings expanding 29.6% YoY

Areas to Watch

NVS4 concerns · Avg: 3.3/10
Revenue GrowthGrowth
0.8%4/10

0.8% revenue growth

Altman Z-ScoreHealth
1.964/10

Grey zone — moderate risk

Debt/EquityHealth
1.183/10

Elevated debt levels

PEG RatioValuation
3.222/10

Expensive relative to growth rate

OSUR4 concerns · Avg: 2.5/10
Market CapQuality
$240.01M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PEG RatioValuation
6.192/10

Expensive relative to growth rate

Return on EquityProfitability
-21.2%2/10

ROE of -21.2% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : NVS

The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 34.6%.

Bull Case : OSUR

The strongest argument for OSUR centers on Price/Book, Debt/Equity, Altman Z-Score.

Bear Case : NVS

The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.

Bear Case : OSUR

The primary concerns for OSUR are Market Cap, Piotroski F-Score, PEG Ratio.

Key Dynamics to Monitor

NVS profiles as a value stock while OSUR is a turnaround play — different risk/reward profiles.

OSUR carries more volatility with a beta of 0.99 — expect wider price swings.

NVS is growing revenue faster at 0.8% — sustainability is the question.

NVS generates stronger free cash flow (5.6B), providing more financial flexibility.

Bottom Line

NVS scores higher overall (51/100 vs 40/100), backed by strong 22.5% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Novartis AG ADR

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.

Visit Website →

OraSure Technologies Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

OraSure Technologies, Inc. develops, manufactures, markets, and sells oral fluid diagnostic products and sample collection devices in the United States, Europe, and internationally. The company is headquartered in Bethlehem, Pennsylvania.

Want to dig deeper into these stocks?